LifeVantage (LFVN) Competitors $14.65 -0.01 (-0.07%) Closing price 04:00 PM EasternExtended Trading$14.60 -0.04 (-0.31%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LFVN vs. AVDL, COGT, OCS, CDMO, QURE, PRAX, AVXL, XERS, CMRX, and ABCLShould you be buying LifeVantage stock or one of its competitors? The main competitors of LifeVantage include Avadel Pharmaceuticals (AVDL), Cogent Biosciences (COGT), Oculis (OCS), Avid Bioservices (CDMO), uniQure (QURE), Praxis Precision Medicines (PRAX), Anavex Life Sciences (AVXL), Xeris Biopharma (XERS), Chimerix (CMRX), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. LifeVantage vs. Avadel Pharmaceuticals Cogent Biosciences Oculis Avid Bioservices uniQure Praxis Precision Medicines Anavex Life Sciences Xeris Biopharma Chimerix AbCellera Biologics Avadel Pharmaceuticals (NASDAQ:AVDL) and LifeVantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, community ranking, valuation and earnings. Is AVDL or LFVN more profitable? LifeVantage has a net margin of 3.46% compared to Avadel Pharmaceuticals' net margin of -52.53%. LifeVantage's return on equity of 34.29% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Avadel Pharmaceuticals-52.53% -93.34% -44.77% LifeVantage 3.46%34.29%15.04% Do analysts rate AVDL or LFVN? Avadel Pharmaceuticals currently has a consensus price target of $19.88, suggesting a potential upside of 143.27%. LifeVantage has a consensus price target of $30.50, suggesting a potential upside of 108.19%. Given Avadel Pharmaceuticals' higher probable upside, equities research analysts plainly believe Avadel Pharmaceuticals is more favorable than LifeVantage.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00LifeVantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor AVDL or LFVN? In the previous week, Avadel Pharmaceuticals had 2 more articles in the media than LifeVantage. MarketBeat recorded 4 mentions for Avadel Pharmaceuticals and 2 mentions for LifeVantage. LifeVantage's average media sentiment score of 1.30 beat Avadel Pharmaceuticals' score of 0.85 indicating that LifeVantage is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avadel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LifeVantage 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in AVDL or LFVN? 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. Comparatively, 35.3% of LifeVantage shares are held by institutional investors. 4.8% of Avadel Pharmaceuticals shares are held by company insiders. Comparatively, 20.7% of LifeVantage shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, AVDL or LFVN? Avadel Pharmaceuticals has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, LifeVantage has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Which has stronger valuation & earnings, AVDL or LFVN? LifeVantage has higher revenue and earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvadel Pharmaceuticals$169.12M4.67-$160.28M-$0.52-15.71LifeVantage$212.15M0.87$2.94M$0.5626.16 Does the MarketBeat Community believe in AVDL or LFVN? Avadel Pharmaceuticals received 126 more outperform votes than LifeVantage when rated by MarketBeat users. However, 77.97% of users gave LifeVantage an outperform vote while only 66.48% of users gave Avadel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAvadel PharmaceuticalsOutperform Votes34966.48% Underperform Votes17633.52% LifeVantageOutperform Votes22377.97% Underperform Votes6322.03% SummaryLifeVantage beats Avadel Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Remove Ads Get LifeVantage News Delivered to You Automatically Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFVN vs. The Competition Export to ExcelMetricLifeVantagePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$183.87M$6.90B$5.63B$8.13BDividend Yield0.98%2.73%4.55%4.00%P/E Ratio26.167.1524.5019.08Price / Sales0.87226.93385.2994.58Price / Cash19.0365.6738.1634.64Price / Book6.166.486.954.36Net Income$2.94M$142.41M$3.20B$247.23M7 Day Performance-10.01%-3.39%-2.42%-0.61%1 Month Performance-14.23%-5.34%2.18%-5.12%1 Year Performance137.06%-7.01%12.85%3.60% LifeVantage Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFVNLifeVantage3.5998 of 5 stars$14.65-0.1%$30.50+108.2%+133.8%$183.87M$212.15M26.16260Positive NewsAVDLAvadel Pharmaceuticals3.5218 of 5 stars$8.84+6.1%$19.88+124.8%-50.6%$854.20M$169.12M-11.1970COGTCogent Biosciences2.1914 of 5 stars$7.39+3.5%$14.43+95.2%+19.4%$841.35MN/A-2.9880News CoveragePositive NewsOCSOculis1.9781 of 5 stars$18.83+0.3%$29.50+56.7%+69.7%$822.16M$980,000.00-9.762Short Interest ↑CDMOAvid Bioservices0.9887 of 5 stars$12.50+0.1%$12.25-2.0%+82.9%$799.18M$139.91M-5.23320High Trading VolumeQUREuniQure2.5314 of 5 stars$14.53+2.3%$38.89+167.6%+168.4%$785.74M$27.12M-2.93500News CoveragePRAXPraxis Precision Medicines2.4701 of 5 stars$38.93+1.7%$123.80+218.0%-29.0%$784.95M$8.55M-3.78110AVXLAnavex Life Sciences3.7601 of 5 stars$9.20-2.4%$44.00+378.3%+110.1%$782.59MN/A-16.7340News CoveragePositive NewsXERSXeris Biopharma3.2741 of 5 stars$5.03+4.4%$5.92+17.6%+178.2%$774.32M$203.07M-11.18290High Trading VolumeCMRXChimerix3.4086 of 5 stars$8.47+0.1%$8.53+0.7%+764.4%$761.76M$159,000.00-9.0190Earnings ReportAnalyst ForecastShort Interest ↓ABCLAbCellera Biologics2.4343 of 5 stars$2.54+0.8%$7.00+175.6%-44.8%$756.89M$28.83M-4.16500 Remove Ads Related Companies and Tools Related Companies Avadel Pharmaceuticals Competitors Cogent Biosciences Competitors Oculis Competitors Avid Bioservices Competitors uniQure Competitors Praxis Precision Medicines Competitors Anavex Life Sciences Competitors Xeris Biopharma Competitors Chimerix Competitors AbCellera Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LFVN) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LifeVantage Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share LifeVantage With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
